Search details
1.
Cardiovascular risk in chronic myeloid leukaemia: A multidisciplinary consensus on screening and management.
Eur J Haematol
; 111(2): 201-210, 2023 Aug.
Article
in English
| MEDLINE | ID: mdl-37186398
2.
A randomised comparison of FLAG-Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial.
Br J Haematol
; 198(3): 528-534, 2022 08.
Article
in English
| MEDLINE | ID: mdl-35388465
3.
Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial.
Haematologica
; 107(7): 1518-1527, 2022 07 01.
Article
in English
| MEDLINE | ID: mdl-34647442
4.
A retrospective observational research study to describe the real-world use of bosutinib in patients with chronic myeloid leukemia in the United Kingdom and the Netherlands.
Eur J Haematol
; 109(1): 90-99, 2022 Jul.
Article
in English
| MEDLINE | ID: mdl-35403752
5.
A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial.
Br J Haematol
; 194(2): 298-308, 2021 07.
Article
in English
| MEDLINE | ID: mdl-33961292
6.
Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study.
Br J Haematol
; 192(1): 62-74, 2021 01.
Article
in English
| MEDLINE | ID: mdl-32449159
7.
The chronic myeloid leukaemia story in the United Kingdom since 1960.
Br J Haematol
; 191(4): 521-526, 2020 11.
Article
in English
| MEDLINE | ID: mdl-33190253
8.
Cancerous inhibitor of protein phosphatase 2A (CIP2A) modifies energy metabolism via 5' AMP-activated protein kinase signalling in malignant cells.
Biochem J
; 476(15): 2255-2269, 2019 08 15.
Article
in English
| MEDLINE | ID: mdl-31350330
9.
Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin.
Am J Hematol
; 94(11): 1236-1243, 2019 11.
Article
in English
| MEDLINE | ID: mdl-31456269
10.
Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trial.
Haematologica
; 103(10): 1654-1661, 2018 10.
Article
in English
| MEDLINE | ID: mdl-29976746
11.
The UK SPIRIT 1 trial in newly diagnosed chronic myeloid leukaemia.
Br J Haematol
; 196(6): e55-e57, 2022 03.
Article
in English
| MEDLINE | ID: mdl-34993961
12.
Molecular monitoring during dose reduction predicts recurrence after TKI cessation in CML.
Blood
; 135(10): 766-769, 2020 03 05.
Article
in English
| MEDLINE | ID: mdl-31935278
13.
A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients.
Blood
; 125(25): 3878-85, 2015 Jun 18.
Article
in English
| MEDLINE | ID: mdl-25833957
14.
Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia.
Blood
; 125(19): 2923-32, 2015 May 07.
Article
in English
| MEDLINE | ID: mdl-25805811
15.
Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial.
Lancet Oncol
; 17(5): 612-21, 2016 05.
Article
in English
| MEDLINE | ID: mdl-27083332
16.
An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation.
Haematologica
; 101(11): 1351-1358, 2016 11.
Article
in English
| MEDLINE | ID: mdl-27540133
17.
Evaluating the use of plerixafor in stem cell mobilisation - an economic analysis of the PHANTASTIC trial.
J Clin Apher
; 31(5): 434-42, 2016 Oct.
Article
in English
| MEDLINE | ID: mdl-26415895
18.
Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Lancet Oncol
; 16(13): 1295-305, 2015 Oct.
Article
in English
| MEDLINE | ID: mdl-26384238
19.
Another set of guidelines for chronic myeloid leukaemia.
Br J Haematol
; 191(2): 147-149, 2020 10.
Article
in English
| MEDLINE | ID: mdl-32712951
20.
Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial.
Br J Haematol
; 170(1): 29-39, 2015 Jul.
Article
in English
| MEDLINE | ID: mdl-25824940